QUIT · Achieve Life Sciences, Inc.

The thesis

AchieveRx's smoking-cessation drug, cytisinicline, can still reach FDA approval by mid-2027, and the shares are more likely than not to beat the S&P 500 over the next three months if the refiling lands on schedule. The FDA rejected the drug in June 2026 over a former manufacturer's plant and incomplete labeling, and the company says it identified no efficacy or safety deficiency. A new drug application (NDA) resubmission naming Adare Pharma Solutions as finished-product manufacturer, planned for the fourth quarter of 2026, decides the case.

The company reported third-quarter results on 10 November 2026 and said the resubmission remains on track for the fourth quarter of 2026, with potential FDA approval by the end of the second quarter of 2027 (company release, 10 November 2026). The same report said Adare had completed three commercial-scale stability batches. The company rebranded as AchieveRx, The Quit Company on 9 November 2026, and the shares now trade under the symbol QUIT.

The shares closed at $6.40 on 10 November 2026, the day of the report, against $6.78 on 9 November 2026, and at $6.45 on 11 November 2026. The report confirmed the timetable without lifting the price. The next fact that matters is the resubmission announcement itself.

Bullish and bearish views on Achieve Life Sciences, Inc.

The bull case on Achieve Life Sciences, Inc. (QUIT), in brief: The timetable held at the third-quarter report. The bear case: Registration batches are not reported.

Bull case

• The timetable held at the third-quarter report. On 10 November 2026 the company said the NDA resubmission is on track for the fourth quarter of 2026, with potential approval by the end of the second quarter of 2027. The 11 August 2026 report had set the same dates.
• Adare has moved past the first batch. The 10 November 2026 release says Adare completed three commercial-scale stability batches. On 11 August 2026 the company had reported one engineering batch.
• The rejection centered on the plant. The complete response letter (CRL), received 20 June 2026, cited current Good Manufacturing Practice observations at a prior third-party facility and labeling not finished by the action date. The company said the FDA identified no efficacy or safety deficiencies (second-quarter report, 11 August 2026).
• Cash rose in the quarter. Cash, cash equivalents and marketable securities were $201.5 million on 30 September 2026, against $187.3 million on 30 June 2026. The company attributed the increase mainly to warrant exercises (10 November 2026 release).
• Quit rates rose over a year. In the open-label ORCA-OL study, four-week continuous abstinence rose from 25.5% in weeks 9–12 to 31.2% in weeks 49–52 among 479 adults who had failed an earlier quit attempt. The company reported no new safety signals from the study's Data Safety Monitoring Committee (10 November 2026 release; CHEST 2026 presentation, 21 October 2026).
• Launch staffing is in place. Benjamin Halladay became chief financial officer on 1 October 2026 and Kaitlyn Tuson became senior vice president of marketing and communications on 7 October 2026 (company releases).
• A second indication carries FDA priority status. The vaping-cessation program has Breakthrough Therapy designation and a Commissioner's National Priority Voucher, and the end-of-Phase 2 meeting has been held (10 November 2026 release).

Bear case

• Registration batches are not reported. The 10 November 2026 release mentions stability batches at Adare and no registration batches. The release lists a possible FDA pre-approval inspection of Adare or other manufacturers among its risk factors.
• A dispute with Sopharma AD is disclosed. The 10 November 2026 release cites a dispute with Sopharma AD and gives no detail. The release does not say what the dispute concerns.
• Overhead is rising with no revenue. Third-quarter operating expenses were $20.5 million against $14.7 million a year earlier, and general and administrative expense was $14.3 million against $9.4 million. Nine-month 2026 net loss was $97.0 million (10 November 2026 release). Cytisinicline is the only drug candidate and there is no product revenue.
• Cheap stock overhangs the shares. The April 2026 placement sold 49.4 million shares at $3.635 and attached 49.5 million warrants at $3.51 (company 8-K, 16 April 2026). Warrant exercises in the third quarter added cash and, by the same mechanism, new shares.
• Generic competition shapes pricing. Cytisinicline would launch against generic varenicline, which could restrain launch pricing and payer coverage in 2027.

Price setup

The shares closed at $6.45 on 11 November 2026. That is 25.3% below the 52-week high of $8.64, reached intraday on 3 September 2026, and 11.0% lower than three months earlier, on adjusted daily closes. The 52-week closing low was $2.65 on 27 March 2026.

The close sits below the 50-day average of $7.22 and above the 200-day average of $5.69, both as of 11 November 2026. Closes since 4 November 2026 have ranged from $6.38 on 5 November 2026 to $6.98 on 4 November 2026.

The market has priced in a refiling on time but not an approval: the shares fell 11.0% over the three months to 11 November 2026 while the company held its fourth-quarter 2026 refiling date at two successive quarterly reports.

Catalysts ahead

• ~31 December 2026 (est.): NDA resubmission for cytisinicline naming Adare as finished-product manufacturer. The company has said the refiling is on track for the fourth quarter of 2026; it is the gating step toward a first-half 2027 approval, and a slip into 2027 delays the whole timeline.
• ~30 June 2027 (est.): Potential FDA approval of cytisinicline. The company anticipates approval by the end of the second quarter of 2027; approval would allow a US launch and set the 20-trading-day window for exercising the remaining April 2026 warrants.

What would change the view

A daily close below $5.75, next to the 200-day average of $5.69, which would show the market doubting the refiling timetable. The case also breaks if the NDA resubmission slips out of the fourth quarter of 2026 or the FDA raises a non-manufacturing issue.

The risks this note tracks, each with what would confirm it:

• The NDA resubmission slips past the fourth quarter of 2026. Confirmed by: A company update moving the refiling into 2027, or no resubmission announcement by the first quarterly report of 2027.
• Manufacturing problems at Adare delay the filing or trigger a second complete response letter. Confirmed by: Disclosure of failed registration batches, missing stability work or adverse FDA inspection findings at Adare.
• The dispute with Sopharma AD, cited in the 10 November 2026 release, affects supply or rights to cytisinicline. Confirmed by: A company filing or release describing the dispute's subject, a legal claim, or a change in the licence terms.
• Placement investors and warrant holders sell into strength, or the company issues new shares. Confirmed by: Form 4 or 13D/G filings showing reduced stakes by lead investors, a registered resale, or a new share offering.
• Rising overhead shortens the funding runway before launch. Confirmed by: Quarterly operating expenses above the $20.5 million of the third quarter of 2026 without a matching rise in cash from warrant exercises.
• Generic varenicline restrains pricing and payer coverage at launch. Confirmed by: Restrictive formulary placement or a launch price below company expectations in 2027 commercial disclosures.

What it trades with

The shares trade on company-specific regulatory news. The CRL, the Adare transfer and the refiling date move them more than the broad market. Reported earnings also swing with the warrants, which are carried as a liability: the second quarter included a $48.7 million non-cash warrant charge, and the third quarter included a $6.9 million non-cash gain (company releases, 11 August 2026 and 10 November 2026). Headline losses therefore say little about the cash cost of running the business.